临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2015年
6期
1004-1005,1006
,共3页
帕洛诺司琼%托烷司琼%化疗药物%恶心%呕吐
帕洛諾司瓊%託烷司瓊%化療藥物%噁心%嘔吐
파락낙사경%탁완사경%화료약물%악심%구토
palonosetron%tropisetron%chemotherapy drugs%nausea%emesis
目的:观察帕洛诺司琼和托烷司琼两种止吐药预防化疗所致恶心、呕吐的临床疗效和安全性。方法74例患者随机分为两组,观察组37例使用帕洛诺司琼,对照组37例采用托烷司琼,比较两组预防急性呕吐(化疗后24 h内)和迟发性呕吐(化疗后2-5天内)的有效率和安全性。结果预防急性呕吐帕洛诺司琼组有效率为89.2%,托烷司琼组有效率为83.8%,两组疗效差异无统计学意义( P>0.05);预防迟发性呕吐帕洛诺司琼组完全缓解率为64.9%,托烷司琼组为40.5%,两组差异有统计学意义( P<0.05)。帕洛诺司琼主要不良反应为头痛、便秘。结论帕洛诺司琼预防急性呕吐的有效率与托烷司琼相当,预防迟发性呕吐的有效率优于托烷司琼,且不良反应轻微。
目的:觀察帕洛諾司瓊和託烷司瓊兩種止吐藥預防化療所緻噁心、嘔吐的臨床療效和安全性。方法74例患者隨機分為兩組,觀察組37例使用帕洛諾司瓊,對照組37例採用託烷司瓊,比較兩組預防急性嘔吐(化療後24 h內)和遲髮性嘔吐(化療後2-5天內)的有效率和安全性。結果預防急性嘔吐帕洛諾司瓊組有效率為89.2%,託烷司瓊組有效率為83.8%,兩組療效差異無統計學意義( P>0.05);預防遲髮性嘔吐帕洛諾司瓊組完全緩解率為64.9%,託烷司瓊組為40.5%,兩組差異有統計學意義( P<0.05)。帕洛諾司瓊主要不良反應為頭痛、便祕。結論帕洛諾司瓊預防急性嘔吐的有效率與託烷司瓊相噹,預防遲髮性嘔吐的有效率優于託烷司瓊,且不良反應輕微。
목적:관찰파락낙사경화탁완사경량충지토약예방화료소치악심、구토적림상료효화안전성。방법74례환자수궤분위량조,관찰조37례사용파락낙사경,대조조37례채용탁완사경,비교량조예방급성구토(화료후24 h내)화지발성구토(화료후2-5천내)적유효솔화안전성。결과예방급성구토파락낙사경조유효솔위89.2%,탁완사경조유효솔위83.8%,량조료효차이무통계학의의( P>0.05);예방지발성구토파락낙사경조완전완해솔위64.9%,탁완사경조위40.5%,량조차이유통계학의의( P<0.05)。파락낙사경주요불량반응위두통、편비。결론파락낙사경예방급성구토적유효솔여탁완사경상당,예방지발성구토적유효솔우우탁완사경,차불량반응경미。
Objective To observe the efficacy and safety of palonosetron and tropisetron to prevent nausea and emesis caused by chemotherapy for cancer. Methods 74 patients were randomly divided into two groups. The group A (n=37) was given palonosetron, and the group B (n=37) was given tropisetron before chemotherapy. The efficiency and safety to prevent acute emesis (during the 24 hours after chemotherapy) and delayed emesis (2-5 days post-chemotherapy) were observed. Results The effective rate to prevent acute emesis ( during the 24 hours after chemotherapy) were 89. 2% for palonosetron and 83. 8% for tropisetron respectively ( P>0. 05 ) . The complete re-sponse rate of delayed emesis was 64. 9% for palonosetron, and 40. 5% for tropisetron (P<0. 05). The adverse re-actions of palonosetron were headache and constipation. Conclusion The effect of palonosetron to prevent acute em-esis is similar with tropisetron, but it is superior to tropisetron for preventing delayed emesis with fewer adverse reac-tions.